Recent 8-K filings for OGEN
Highest-materiality recent filing
Oragenics dosed first patient in Phase IIa concussion trial; signs LOI for CNS device
- Phase IIa trial of ONP-002 in Australia active; first patient dosed at Mackay Base Hospital March 2026.
- Signed LOI to license a complementary CNS medical device; expands addressable indication set beyond ONP-002.
-
Oragenics dosed first patient in Phase IIa concussion trial; signs LOI for CNS device
Phase IIa trial of ONP-002 in Australia active; first patient dosed at Mackay Base Hospital March 2026.
-
Oragenics signs LOI to license CardioDialysis from Sigyn Therapeutics for TBI
LOI grants Oragenics exclusive license for CardioDialysis blood purification tech in TBI and chronic neurodegenerative diseases.
-
Oragenics dosed first patient in Phase IIa trial of ONP-002 for mild traumatic brain injury
First patient dosed at Mackay Hospital (Australia) days after site activation on March 31, 2026.
-
Board scheduled 2025 Annual Meeting for June 29, 2026, more than 30 days from 2024 meeting anniversary.
-
Received final HREC approval in Australia for Phase IIa trial of ONP-002 for concussion/mTBI.
-
Oragenics extends ATM equity distribution agreement with Dawson James
On January 22, 2026, Oragenics amended its at-the-market sales agreement with Dawson James Securities.
-
Oragenics CEO presents at Sequire Investor Summit; filing lacks specific financial data
CEO presented at Sequire Investor Summit on January 20, 2026, using a new corporate presentation.
-
Oragenics board boosts CEO salary 5% to $341,250, awards bonus and options
CEO Janet Huffman base salary increased 5% from $325,000 to $341,250 effective Jan 1, 2026.
-
Regained NYSE American compliance on Oct 20, 2025, resolving equity deficiency and removing below-compliance indicator.
-
Oragenics settles Ladenburg dispute for $700K; regains NYSE American compliance
Paid $700K to Ladenburg Thalmann to settle $2.5M fee dispute; mutual release and arbitration dismissal.
-
Oragenics appoints Natasha Giordano to board of directors effective Sept 1, 2025
Natasha Giordano appointed to Oragenics Board effective September 1, 2025.
-
Oragenics raises $16.5M, advances ONP-002 Phase IIa concussion trial for Q3 2025
Raised $16.5M via Series H Preferred Stock and Warrants; net proceeds ~$15.2M after fees.
-
Oragenics closes $16.5M public offering of Series H Preferred Stock and Warrants
Issued 660,000 shares of Series H Convertible Preferred Stock at $25/unit with warrants to buy 660,000 additional shares.
-
Oragenics approves 1-for-30 reverse stock split to meet NYSE American listing standards
Reverse stock split at 1-for-30 ratio; effective 12:01 a.m. ET on June 3, 2025.
-
Oragenics furnishes Neurotrauma Medicine presentation; no specifics disclosed
Presentation on Neurotrauma Medicine provided for Scientific Advisory Board webinar on May 20, 2025.
-
Janet Huffman, previously CFO and Interim CEO, appointed permanent CEO effective May 2, 2025 under one-year agreement.
-
Oragenics submits Phase II concussion trial protocol to NZ ethics committee
Submitted clinical trial protocol to Health and Disability Ethics Committee (HDEC) in New Zealand for Phase II trial of ONP-002 for mild traumatic brain injury.
-
Oragenics Q1 update: $5M raised, ONP-002 Phase IIa trial advances
Raised ~$2.6M via ATM equity and ~$2.25M via non-dilutive debt; submitted DoD grant for concussion program.
-
Oragenics submits Investigator's Brochure for Phase II trial of ONP-002 in Australia
Phase II trial of intranasal neurosteroid ONP-002 for mild traumatic brain injury (mTBI); up to 40 participants enrolled across two arms.
-
Oragenics sets 2024 Annual Meeting for May 16, 2025; shareholder proposal deadline March 14
Board scheduled 2024 Annual Meeting for May 16, 2025, over 30 days later than 2023 meeting anniversary.
Materiality & sentiment trend
Max materiality 0.75 · Median 0.57 · Most common event other_material